Dana M. Chase, MD

Dana M. Chase, MD

Gynecologic Oncology
Accepting new patients
Primary Location
UCLA Health OBGYN Oncology
100 Medical Plaza
Suite 383
Los Angeles, California 90095


Dr. Chase is an associate professor of UCLA Obstetrics and Gynecology in the Division of Gynecologic Oncology. She completed her medical degree, residency in obstetrics and gynecology and gynecologic oncology fellowship at the University of California, Irvine.  Her clinical and research interests include clinical trials, chemotherapy, quality of life, the microbiome, health disparities, and geriatric oncology. Dr. Chase is a board-certified gynecologic cancer physician and surgeon.


Spanish, English


Medical Board Certifications

Gynecologic Oncology, American Board of Obstetrics and Gynecology, 2014
Obstetrics and Gynecology, American Board of Obstetrics and Gynecology, 2009


UC Irvine Medical Center, 2011


UC Irvine Medical Center, 2007


UC Irvine School of Medicine, MD, 2003


  • Honor Health Physician Recognition Award for Patient Experience, 2022
  • Top Doctor, Phoenix Magazine, 2022, 2021
  • Overall Provider Award, Rating Silver with Near Perfect Score of 90-96, Dignity Health Medical Group, 2016
  • See More

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Areas of Focus

Vulvar cancer
Minimally invasive gynecologic surgery
Ovarian cancer
Uterine cancer
Endometrial cancer
Cervical cancer



  1. Chase DM, Crade M, Basu T, Saffari B, Berman ML.  Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound.  Int J Gynecol Cancer. 2009 Apr;19(3):354-60.
  2. Chase DM, Lopez S, Nguyen C, et al. A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology? American journal of obstetrics and gynecology.  Am J Obstet Gynecol. 2008 Nov;199(5):541.e1-7
  3. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR.   Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma.  Gynecol Oncol. 2009 Dec;115(3):339-42.
  4. Chase DM Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 2012 Sep;126(3):375-80.
  5. Chase DM, Kauderer J, Wenzel L, Ramondetta L, Cella D, Long HJ 3rd, Monk BJ. Factors Associated With Grade 3 or 4 Treatment-Related Toxicity in Women With Advanced or Recurrent Cervical Cancer: An Exploratory Analysis of NRG Oncology/Gynecologic Oncology Group Trials 179 and 204. Int J Gynecol Cancer. 2015 Feb;25(2):303-8.
  6. Chase DM, Huang H, Foss CD, Wenzel LB, Monk BJ, Burger RA. Neurotoxicity in Ovarian Cancer Patients on Gynecologic Oncology Group (GOG) Protocol 218:  Characteristics Associated with Toxicity and the Effect of Substitution with Docetaxel:  An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Feb;136(2):323-7
  7. Łaniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, Greenspan DL, Chase DM, Herbst-Kralovetz MM, Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci Rep. 2019 May 14
  8. Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 May;30(5):596-601. doi: 10.1136/ijgc-2019-000869. Epub 2020 Feb 28. Erratum in: Int J Gynecol Cancer. 2020 Aug;30(8):1267. PMID: 32114513; PMCID: PMC7780262.
  9. Chase DM, Salani R, Farley J, Torres T, Stone J. Unwittingly biased: A note to gynecologic cancer providers. Gynecol Oncol. 2021 Mar;160(3):646-648. doi: 10.1016/j.ygyno.2021.01.009. Epub 2021 Jan 20. PMID: 33485640.
  10. Chase DM, Neighbors J, Perhanidis J, Monk BJ. Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay. Gynecol Oncol. 2021 Jun;161(3):832-837. doi: 10.1016/j.ygyno.2021.03.021. Epub 2021 Apr 1. PMID: 33814195.
  11. Chase DM, Marín MR, Backes F, Han S, Graybill W, Mirza MR, Pothuri B, Mangili G, O'Malley DM, Berton D, Willmott L, Baumann K, Coleman RL, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl FM, Woodward T, Monk BJ, Gonzalez-Martin A; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022 Sep;166(3):494-502. doi: 10.1016/j.ygyno.2022.06.028. Epub 2022 Jul 15. PMID: 35851489.


  • Honor Health Physician Recognition Award for Patient Experience, 2022
  • Top Doctor, Phoenix Magazine, 2022, 2021
  • Overall Provider Award, Rating Silver with Near Perfect Score of 90-96, Dignity Health Medical Group, 2016
  • St. Joseph’s Hospital Teacher of the Year Award for Obstetrics and Gynecology, Dignity Health St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 2016
  • American Association of Obstetricians and Gynecologists Foundation (AAOGF) and the American Gynecological and Obstetrical Society (AGOS), 2015 AGOS Annual Meeting, Half Moon Bay, CA, 2015
  • Vitals Top 10 Doctor Award, Obstetrics and Gynecology, American Registry, Delray Beach, FL, 2013
  • Young Doctor Summit Award, 14th Biennial International Gynecologic Cancer Society, 2012
  • Oncology Trainee Travel Award, The Conquer Cancer Foundation of ASCO, 2011
  • ASCO Cancer Foundation Merit Award, 2009